PostEra closes $24M in new financing to advance drug discovery

By The Science Advisory Board staff writers

January 12, 2022 -- PostEra has closed $24 million in equity financing to accelerate medicinal chemistry and bring new cures to patients. The company also announced a multitarget strategic partnership with Pfizer to establish an artificial intelligence lab.

The proceeds will go toward advancing a series of partnered drug discovery programs and further developing PostEra's medicinal chemistry platform.

Over the past 18 months, PostEra has proven its platform on a wide variety of drug discovery programs by tightly integrating the design-make-test cycle of medicinal chemistry, the company said. Recent results include the rapid development of COVID oral antiviral candidates via COVID Moonshot and the advancement of several drug discovery efforts with biopharma partners.

PostEra was founded in 2019. The Clermont Group led the series A financing with participation from Breyer Capital, Lifeforce Capital, I2BF Global Ventures, and existing investors Metaplanet, HOF Capital, Ace & Company, Pioneer Fund, and R. Martin Chavez.


Copyright © 2022 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here